Premium
Letter: risk of severe COVID‐19 outcomes associated with inflammatory bowel disease medications—reassuring insights from the United Kingdom PREPARE‐IBD multicentre cohort study
Author(s) -
Lamb Christopher A.,
Sebastian Shaji,
Kent Alexandra J.,
Segal Jonathan P.,
Gonzalez Haidee A.,
Brookes Matthew J.,
Mehta Shameer J.,
Subramanian Sreedhar,
Bhala Neeraj,
Hicks Lucy C.,
Conley Thomas E.,
Patel Kamal V.,
Walker Gareth J.,
Kennedy Nicholas A.
Publication year - 2021
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16349
Subject(s) - medicine , inflammatory bowel disease , covid-19 , inflammatory bowel diseases , cohort , cohort study , medline , disease , intensive care medicine , pathology , outbreak , infectious disease (medical specialty) , political science , law